Fovargue, Sara J. (2005) A Leap of Faith? Sanctioning Xenotransplant Clinical Trials. Liverpool Law Review, 26 (2). pp. 125-147. ISSN 1572-8625Full text not available from this repository.
Introducing a new medical technique, procedure or drug to the public via clinical trials is risky at the best of times. When the trial involves a biotechnology which holds out the promise of prolonging, if not saving, life the push to move from the laboratory to clinical trials may be hard to resist. In this article I explore whether the regulatory scheme for clinical trials in the UK is able to accommodate developing technologies by considering how the current legal and ethical frameworks determine when a procedure such as xenotransplantation should proceed to trials. In particular, I discuss whether basing our regulatory schemes on the principles espoused in the Declaration of Helsinki offer sufficient protection to those who may be affected by xenotransplant trials – the recipient, their health-care workers, close contacts and, unusually, the wider public. I question whether it is possible for a technology to be approved for clinical trials when allowing such trials may benefit the individual but ultimately negatively impact on society as a whole.
|Journal or Publication Title:||Liverpool Law Review|
|Uncontrolled Keywords:||clinical trials - organs - regulation - risk - therapeutic benefit - xenotransplantation|
|Subjects:||K Law > K Law (General)|
|Departments:||Faculty of Arts & Social Sciences > Law School|
|Deposited By:||Dr Sara Fovargue|
|Deposited On:||03 Dec 2008 13:12|
|Last Modified:||03 Nov 2015 14:35|
Actions (login required)